Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration
13.9.2021 16:00:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/
Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)
juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3
Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:
- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4
- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.
- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity.5
Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:
- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars
- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars
Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.
juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.
"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.
1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier
2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224
3 available with CE 0373
4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.
5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.
PRJ0821
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005466/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Network X 2026 Brings Europe’s Telecom Leaders Together in Vienna to Define the Future of Connectivity8.10.2026 13:42:00 EEST | Press release
Network X 2026 unites the telecommunications industry’s most influential executives and technology leaders at VIECON Vienna from 13-15 October, with a high-powered Headliners programme focused on the forces reshaping the future of connectivity. Across three days, CEOs, CTOs, technology chiefs, regulators and industry experts from leading operators and technology organisations will examine how artificial intelligence, network sovereignty, broadband networks, 6G, cloud, infrastructure investment and new business models are changing the role of the telecom operator. The programme features senior executives from A1 Group, Swisscom, Drei Austria, A1 Austria, Orange, Deutsche Telekom, Vodafone Group, Kyivstar, 4iG Telecommunications Holding, Yettel Bulgaria, Play Poland, Orange Slovensko, NGMN Alliance and other major players across the global connectivity ecosystem. Industry Leaders Take the Stage Network X 2026 will feature a series of keynote presentations, fireside conversations and high
iQmetrix Appoints Beniamin Longodor as Vice President of Global Growth8.10.2026 13:00:00 EEST | Press release
iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, today announced the appointment of Beniamin Longodor as Vice President of Global Growth. Beniamin joins from NTS Retail where he has long been the Head of Global Sales. In this newly created role, Beniamin will lead iQmetrix’s efforts to further grow its footprint with telcos, retailers, and partners outside of its core North American market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008507325/en/ Beniamin Longodor, Vice President of Global Growth at iQmetrix Beniamin brings over 18 years of experience in telecom commerce software, business development, and partner management. His appointment comes as telecom operators and retailers worldwide look to replace fragmented legacy systems with a single, intelligent commerce layer across their stores, channels, and markets. iQmetrix solutions already power more than $17BN in annual sales a
TensorX Reaches $5 Million and Appoints Tim Grant as CEO as Demand for Sovereign AI Accelerates8.10.2026 11:19:00 EEST | Press release
TensorX, the Irish sovereign AI inference company, has reached $5 million in revenue as demand for private AI infrastructure continues to grow across Europe and beyond. Tim Grant, who joined the company as Executive Chairman in May, has been appointed Chief Executive Officer to lead as its growth accelerates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008373051/en/ Tim Grant, Executive Chairman since May, is appointed Chief Executive Officer as the Dublin company serves more than 5,000 paying customers and expands its infrastructure across Europe. TensorX is a neocloud that delivers inference on open-source AI models using dedicated NVIDIA GPUs with zero data retention, so customer data is not stored, reused or sent outside Europe. Since it began serving customers, the company has raised $10 million in seed funding led by Darius Cubed Ventures. Over seven months, TensorX’s paying customer base grew to over 5,000, rang
Aresbank Strengthens Trade Finance and Correspondent Banking Compliance with SymphonyAI8.10.2026 10:55:00 EEST | Press release
As a specialized corporate and trade finance bank in the MENA region, Aresbank manages risk and moves money across some of the most sensitive trade corridors between Europe, the Middle East and North Africa. Operating in a highly regulated environment, Aresbank turned to SymphonyAI, a global leader in Vertical AI whose financial crime compliance platform already spans retail, commercial and correspondent banking, to strengthen its transaction monitoring framework across trade finance and correspondent banking. Headquartered in Madrid, the bank's business centers on trade instruments, including correspondent banking, documentary credits, international guarantees and multi-currency credit lines that connect European and MENA markets. Correspondent banking carries a distinct risk profile, and trade finance flows in the region remain a focus for regulators concerned with sanctions evasion and trade-based money laundering. Aresbank has selected SymphonyAI's transaction monitoring capabiliti
Fortune Media and Great Place To Work Name Experian As One Of The ‘100 Best Companies to Work For Europe’ in 2026 for Second Year8.10.2026 10:00:00 EEST | Press release
Great Place To Work® and Fortune Europe have recognised Experian as one of the Fortune 100 Best Companies to Work For™ Europe for the second-year running. The 100 Best Companies to Work For Europe list is a comprehensive recognition for business excellence and employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Great Place To Work evaluates confidential feedback from employees, validating against HR data from participating companies. Only companies with consistently high survey responses from employees — regardless of their role, department, or status in the company — are honored with placement on the list. Eligible companies have 500 or more employees and were represented on at least one national Best Workplaces™ List in Europe. Jacky Simmonds, Chief People Officer, Experian, said: “We are thrilled to being named one of the Fortune 100 Best Companies to Work For™ in Europe for the second year in a row. It’s an incredibly proud moment for us at Experian
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom